Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C14H22N4 |
| Molecular Weight | 246.3513 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCN1CCC[C@@H]2CC3=C(C[C@@H]12)C=NC(N)=N3
InChI
InChIKey=TUFADSGTJUOBEH-ZWNOBZJWSA-N
InChI=1S/C14H22N4/c1-2-5-18-6-3-4-10-7-12-11(8-13(10)18)9-16-14(15)17-12/h9-10,13H,2-8H2,1H3,(H2,15,16,17)/t10-,13-/m1/s1
| Molecular Formula | C14H22N4 |
| Molecular Weight | 246.3513 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Quinelorane is an octahydropyrimido[4,5-g]quinolone derivative patented by American pharmaceutical company Eli Lilly and Co. as for the treatment anxiety, Parkinson's syndrome, depression, and hypertension. Quinelorane acts as an agonist of dopamine agonist for the D2 and D3 receptors. In preclinical studies Quinelorane (IM) treatment produced dose-dependent effects on male sexual responding. Penile erections and masturbation were markedly facilitated following treatment with either 2.5 or 5 micrograms/kg quinelorane. Higher doses of quinelorane (10 and 25 micrograms/kg) generally did not further augment sexual responding but rather resulted in a return in sexual responding to control vehicle levels. Quinelorane had a biphasic effect on yawning behavior of the monkeys with low doses (2.5 and 5 micrograms/kg) facilitating yawning and high doses (25 micrograms/kg) inhibiting yawning.
CNS Activity
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Neural basis for a heritable phenotype: differences in the effects of apomorphine on startle gating and ventral pallidal GABA efflux in male Sprague-Dawley and Long-Evans rats. | 2009-12 |
|
| Penile erection and yawning induced by dopamine D2-like receptor agonists in rats: influence of strain and contribution of dopamine D2, but not D3 and D4 receptors. | 2009-07 |
|
| Quinelorane, a dopamine D3/D2 receptor agonist, reduces prepulse inhibition of startle and ventral pallidal GABA efflux: time course studies. | 2008-10 |
|
| Decrease of D2 receptor binding but increase in D2-stimulated G-protein activation, dopamine transporter binding and behavioural sensitization in brains of mice treated with a chronic escalating dose 'binge' cocaine administration paradigm. | 2008-08 |
|
| Lack of D2 receptor mediated regulation of dopamine synthesis in A11 diencephalospinal neurons in male and female mice. | 2008-06-12 |
|
| Lack of self-administration of cocaine in dopamine D1 receptor knock-out mice. | 2007-11-28 |
|
| D2-like receptors in nucleus accumbens negatively modulate acetylcholine release in prefrontal cortex. | 2007-09 |
|
| Action of novel antipsychotics at human dopamine D3 receptors coupled to G protein and ERK1/2 activation. | 2007-08 |
|
| Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists. | 2007-08 |
|
| Effects of selective dopamine D1-like and D2-like agonists on prepulse inhibition of startle in inbred C3H/HeJ, SPRET/EiJ, and CAST/EiJ mice. | 2007-04 |
|
| Insulin replacement restores the behavioral effects of quinpirole and raclopride in streptozotocin-treated rats. | 2007-03 |
|
| Dopamine transporter (DAT) inhibitors alleviate specific parkinsonian deficits in monkeys: association with DAT occupancy in vivo. | 2006-11 |
|
| D2-like receptors mediate the expulsion phase of ejaculation elicited by 8-hydroxy-2-(di-N-propylamino)tetralin in rats. | 2006-02 |
|
| A reconfiguration of CaV2 Ca2+ channel current and its dopaminergic D2 modulation in developing neostriatal neurons. | 2005-12 |
|
| Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis. | 2005-07 |
|
| Perinatal exposure to low levels of the environmental antiandrogen vinclozolin alters sex-differentiated social play and sexual behaviors in the rat. | 2005-06 |
|
| Dopamine D3 modulation of locomotor activity and sleep in the nucleus accumbens and in lobules 9 and 10 of the cerebellum in the rat. | 2005-06 |
|
| Dopamine D1 and D2 agonist effects on prepulse inhibition and locomotion: comparison of Sprague-Dawley rats to Swiss-Webster, 129X1/SvJ, C57BL/6J, and DBA/2J mice. | 2005-02 |
|
| Delta-9-tetrahydrocannabinol differentially suppresses emesis versus enhanced locomotor activity produced by chemically diverse dopamine D2/D3 receptor agonists in the least shrew (Cryptotis parva). | 2005-01 |
|
| Physicochemical modulation of agonist-induced [35s]GTPgammaS binding: implications for coexistence of multiple functional conformations of dopamine D1-like receptors. | 2005 |
|
| Mapping the effects of the selective dopamine D2/D3 receptor agonist quinelorane using pharmacological magnetic resonance imaging. | 2005 |
|
| Quantification and pharmacological characterization of dialysate levels of noradrenaline in the striatum of freely-moving rats: release from adrenergic terminals and modulation by alpha2-autoreceptors. | 2004-12-30 |
|
| Differential effects of dopaminergic agents on locomotor sensitisation and on the reinstatement of cocaine-seeking and food-seeking behaviour. | 2004-10 |
|
| Dopamine D3 receptor ligands modulate the acquisition of morphine-conditioned place preference. | 2004-09 |
|
| Blockade by the cannabinoid CB1 receptor antagonist, rimonabant (SR141716), of the potentiation by quinelorane of food-primed reinstatement of food-seeking behavior. | 2004-05 |
|
| Neuromodulation of the locomotor network by dopamine in the isolated spinal cord of newborn rat. | 2004-03 |
|
| Protection against cocaine toxicity in mice by the dopamine D3/D2 agonist R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol [(+)-PD 128,907]. | 2004-03 |
|
| Modulation of the discriminative stimulus effects of mu opioid agonists in rats: II. Effects of dopamine D2/3 agonists. | 2004-02 |
|
| Modulation of the locomotor activating effects of the noncompetitive NMDA receptor antagonist MK801 by dopamine D2/3 receptor agonists in mice. | 2004-02 |
|
| Effects of dopamine indirect agonists and selective D1-like and D2-like agonists and antagonists on cocaine self-administration and food maintained responding in rats. | 2004 |
|
| Dopaminergic modulation of behavioral states in mesopontine tegmentum: a reverse microdialysis study in freely moving cats. | 2003-11-01 |
|
| Effects of a dopamine D3 receptor ligand, BP 897, on acquisition and expression of food-, morphine-, and cocaine-induced conditioned place preference, and food-seeking behavior in rats. | 2003-11 |
|
| Gradient of dopamine responsiveness to dopamine receptor agonists in subregions of the rat nucleus accumbens. | 2003-09-12 |
|
| Facilitatory effect of the dopamine D4 receptor agonist PD168,077 on memory consolidation of an inhibitory avoidance learned response in C57BL/6J mice. | 2003-06-16 |
|
| The modulatory actions of dopamine D2/3 agonists and antagonists on the locomotor-activating effects of morphine and caffeine in mice. | 2003-05 |
|
| Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of alpha 2A-adrenoceptors: a dialysis comparison to talipexole and quinelorane in the absence of acetylcholinesterase inhibitors. | 2003-04 |
|
| Dopaminergic inhibition of secretin-stimulated choleresis by increased PKC-gamma expression and decrease of PKA activity. | 2003-04 |
|
| Respective roles of dopamine D2 and D3 receptors in food-seeking behaviour in rats. | 2003-02 |
|
| D2-like receptor-mediated inhibition of Na+-K+-ATPase activity is dependent on the opening of K+ channels. | 2002-07 |
|
| Role of dopamine D2-like receptors in cocaine self-administration: studies with D2 receptor mutant mice and novel D2 receptor antagonists. | 2002-04-01 |
|
| Deletion of CCK2 receptor in mice results in an upregulation of the endogenous opioid system. | 2002-03-01 |
|
| Dopamine D1/5 receptor stimulation induces c-fos expression in the subthalamic nucleus: possible involvement of local D5 receptors. | 2002-01 |
|
| Dopamine D2 receptor-mediated G-protein activation in rat striatum: functional autoradiography and influence of unilateral 6-hydroxydopamine lesions of the substantia nigra. | 2001-11-30 |
|
| In vivo characterization of basal amino acid levels in subregions of the rat nucleus accumbens: effect of a dopamine D(3)/D(2) agonist. | 2001-09 |
|
| Nonlinear analysis of partial dopamine agonist effects on cAMP in C6 glioma cells. | 2001-08-08 |
|
| Influence of social isolation and 6-OHDA lesion on the effects of quinelorane. | 2001-06-23 |
|
| An investigation of the mechanisms responsible for acute fluoxetine-induced anxiogenic-like effects in mice. | 2001-06 |
|
| Evidence to suggest that agonist modulation of hyperlocomotion is via post-synaptic dopamine D2 or D3 receptors. | 1997-06 |
|
| Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy. | 1995-11 |
|
| Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor. | 1992-04-10 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:20:32 GMT 2025
by
admin
on
Mon Mar 31 19:20:32 GMT 2025
|
| Record UNII |
Z0X4VT3Y1Q
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C66884
Created by
admin on Mon Mar 31 19:20:32 GMT 2025 , Edited by admin on Mon Mar 31 19:20:32 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL155731
Created by
admin on Mon Mar 31 19:20:32 GMT 2025 , Edited by admin on Mon Mar 31 19:20:32 GMT 2025
|
PRIMARY | |||
|
QUINELORANE
Created by
admin on Mon Mar 31 19:20:32 GMT 2025 , Edited by admin on Mon Mar 31 19:20:32 GMT 2025
|
PRIMARY | |||
|
6042
Created by
admin on Mon Mar 31 19:20:32 GMT 2025 , Edited by admin on Mon Mar 31 19:20:32 GMT 2025
|
PRIMARY | |||
|
100000080275
Created by
admin on Mon Mar 31 19:20:32 GMT 2025 , Edited by admin on Mon Mar 31 19:20:32 GMT 2025
|
PRIMARY | |||
|
C047726
Created by
admin on Mon Mar 31 19:20:32 GMT 2025 , Edited by admin on Mon Mar 31 19:20:32 GMT 2025
|
PRIMARY | |||
|
C152121
Created by
admin on Mon Mar 31 19:20:32 GMT 2025 , Edited by admin on Mon Mar 31 19:20:32 GMT 2025
|
PRIMARY | |||
|
Z0X4VT3Y1Q
Created by
admin on Mon Mar 31 19:20:32 GMT 2025 , Edited by admin on Mon Mar 31 19:20:32 GMT 2025
|
PRIMARY | |||
|
DTXSID4046315
Created by
admin on Mon Mar 31 19:20:32 GMT 2025 , Edited by admin on Mon Mar 31 19:20:32 GMT 2025
|
PRIMARY | |||
|
57242
Created by
admin on Mon Mar 31 19:20:32 GMT 2025 , Edited by admin on Mon Mar 31 19:20:32 GMT 2025
|
PRIMARY | |||
|
97466-90-5
Created by
admin on Mon Mar 31 19:20:32 GMT 2025 , Edited by admin on Mon Mar 31 19:20:32 GMT 2025
|
PRIMARY | |||
|
SUB10209MIG
Created by
admin on Mon Mar 31 19:20:32 GMT 2025 , Edited by admin on Mon Mar 31 19:20:32 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST | |||
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
